历史财报显示，2022年-2024年，热景生物的营业收入与净利润均连续3年下滑。其中，营收同比依次下 滑33.76%、84.78%与6.74%；2022年与2023年净利润依次下滑56.78%、97.1%，2024年公司由盈转亏， 净利润为-1.91亿元，这也是公司上市后首次出现年度亏损。 公开信息显示，热景生物创立于2005年，是一家聚焦生物医药领域的高新技术企业，主营业务涉及研 发、生产和销售体外诊断试剂及仪器。2019年9月，公司登陆上海证券交易所科创板。公司所属的IVD （体外诊断）板块指数（申万）今年以来累计上涨8.25%。 【深圳商报讯】（记者 詹钰叶）在亏损3年后，热景生物今年前三季度连续亏损，净利润为-1.09亿元。 受益于创新药受追捧，公司今年以来股价大涨。不过，数名股东最近半年轮番进行大手笔减持。 热景生物三季报显示，前三季度公司实现营业收入3.1亿元，同比下降19.8%；归属母公司股东的净利润 为-1.09亿元，亏损同比扩大168.12%；基本每股收益为-1.23元。公告提到，报告期内公司业绩下滑，主 要受到体外诊断行业集采政策影响，导致产品价格下降和短期需求减少。 ...

三季度末养老金账户出现在海泰新光、鼎通科技、热景生物、凯因科技前十大流通股东榜。 | 代码 | 简称 | 养老金家 | 养老金持股量（万 | 环比 | 占流通股比例 | 持股市值（万 | | --- | --- | --- | --- | --- | --- | --- | | | | 数 | 股） | （%） | （%） | 元） | | 688677 | 海泰新 光 | 1 | 503.46 | -0.08 | 4.20 | 25021.71 | | 688668 | 鼎通科 技 | 2 | 151.74 | 新进 | 1.09 | 14401.61 | | 688068 | 热景生 物 | 1 | 150.01 | 新进 | 1.62 | 25489.67 | | 688687 | 凯因科 技 | 1 | 87.26 | 新进 | 0.51 | 2443.15 | （文章来源：证券时报网） 基本养老保险基金八零二组合为海泰新光第四大流通股东，持股量为503.46万股，占流通股比例 4.20%。基本养老保险基金一九零六组合、基本养老保险基金一六零五二组合为鼎通科技第七大、第九 大流通股东，合计持股量为15 ...

Investment Rating - The report maintains a "Positive" investment rating for the pharmaceutical and biotechnology industry [1] Core Insights - The report highlights significant advancements in innovative drugs, particularly in the context of recent clinical trial results presented at the 2025 ESMO conference, showcasing the potential for new treatment options in various cancer types [12][19] - The report emphasizes the emergence of domestic drugs that have achieved notable efficacy in treating conditions such as NSCLC and HER2-positive breast cancer, indicating a shift in the competitive landscape [13][17] Summary by Sections 1. New Drug Developments - **2L EGFR Mutant NSCLC**: The drug Lukanosumab (sac-TMT) is the first to demonstrate both overall survival (OS) and progression-free survival (PFS) benefits in patients with TKI-resistant NSCLC, with mPFS of 8.3 months compared to 4.3 months for chemotherapy [13][14] - **HER2 Positive Breast Cancer**: The drug Ruikang Trastuzumab shows longer mPFS of 30.6 months compared to 8.3 months for the chemotherapy combination, indicating a promising new option for patients [17][18] - **T-Bren for Breast Cancer**: Early data from the T-Bren trial shows a clinical overall response rate (cORR) of 82.2% in HER2-positive patients, with mPFS of 18.0 months [19][20] - **2L HER2 Positive Gastric Cancer**: Anniotuzumab combined with chemotherapy shows significant improvements in mPFS (7.1 months vs 2.7 months) and mOS (19.6 months vs 11.5 months), suggesting a potential shift in treatment paradigms [21][24] 2. Market Performance - The pharmaceutical and biotechnology sector saw a 0.58% increase in October, underperforming the CSI 300 index by 2.67 percentage points, ranking 25th among 31 sub-industries [25][30] - The medical research outsourcing sector experienced the highest growth, up 5.47%, while other bioproduct sectors faced declines [30][34]

热景生物 20251024 摘要 热景生物前三季度营收有所扩大，但经营现金流显著改善，实现正向现 金流 100 多万元，去年同期为负 900 多万元。研发投入占营收比例为 21.79%，主要集中在 IVD 板块，创新药研发投入持续增加。 顺景医药 SBC001 心梗项目完成 EB 阶段数据分析，取得积极初步疗效。 姚景基因小核酸药研发获多项专利，肝外递送系统有积极进展。正元生 物 AD 治疗项目 AA001 完成 1A 临床，准备启动 1B 临床研究。 SBC001 急性心梗项目预计 2025 年底至 2026 年初启动二期临床，目 前正积极准备方案，并与国内外专家沟通。Q4 期间将积极推动二期试 验启动。 SPC001 正积极推动附条件上市，并申请北京市重大项目支持。同时， 与海外合作伙伴交流，计划在大中华区以外地区开展临床研究，加速商 业化。 智源生物 AA001 阿尔茨海默病治疗项目已完成一期临床 EA 阶段，安全 性、耐受性良好，半衰期较长，预计 2026 年上半年完成一期临床。公 司合作推进 AD 诊断产品开发。 Q&A 请介绍一下瑞幸生物 2025 年第三季度的财务表现及主要进展。 2025 年 ...

| 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 920300 | 辰光医疗 | 17.51 | -8.80% | 12.40万 | | 2.21亿 | | 300642 | 透景生命 | 22.95 | -5.40% | 17.57万 | | 4.10亿 | | 688677 | 海泰新光 | 48.50 | -5.05% | - 3.88万 | | 1.93亿 | | 688108 | 赛诺医疗 | 28.00 | -4.73% | 26.37万 | | 7.40亿 | | 688013 | 天臣医疗 | 55.66 | -3.98% | 1.92万 | | 1.10亿 | | 300289 | 利德曼 | 7.70 | -3.39% | 24.65万 | | 1.91亿 | | 301234 | 五洲医疗 | 43.80 | -2.86% | 1.29万 | | 5756.36万 | | 688068 | 热景生物 | 160.46 | -2.84% | 3.13万 | | ...

Core Insights - On October 23, 2023, brokerage firms provided target prices for listed companies, with significant increases noted for companies in the pet feed and communication equipment sectors, specifically Guibao Pet, StarNet RuiJie, and Weisheng Information, with target price increases of 61.09%, 50.73%, and 43.78% respectively [1][2]. Target Price Increases - Guibao Pet (301498) received a target price of 118.00 yuan, reflecting a target price increase of 61.09% from the latest closing price [2]. - StarNet RuiJie (002396) has a target price of 39.16 yuan, with a target price increase of 50.73% [2]. - Weisheng Information (688100) has a target price of 51.00 yuan, showing a target price increase of 43.78% [2]. - Other notable companies include China Unicom (600050) with a target price increase of 36.22% and Wens Foodstuff Group (300498) with an increase of 33.28% [2]. Brokerage Recommendations - A total of 59 listed companies received brokerage recommendations on October 23, with Tonghuashun (300033) receiving the highest number of recommendations at 5, followed by Guibao Pet with 4, and Meihua Biological (600873) with 3 [3][4]. - The sectors represented include software development, feed, and chemical products [4]. Rating Adjustments - On October 23, only one company, Huayou Cobalt (603799), had its rating upgraded from "Hold" to "Buy" by Huayuan Securities [5]. - This indicates a positive outlook for the energy metals sector [5]. First-Time Coverage - Nine companies received first-time coverage from brokerages on October 23, with notable mentions including Innovation New Materials (600361) rated "Buy" by Huayuan Securities, and YunTu Holdings (002539) and Meihua Biological (600873) both rated "Buy" by Global Fortune Financial [6]. - Other companies receiving first-time ratings include Babi Food (605338) and Shengquan Group (108850) [6].

Core Insights - The report indicates that as of October 23, 2025, institutional investors hold a total of 18.22 million shares of Hotgen Biotech (688068.SH), representing 19.65% of the company's total share capital, which is a decrease of 2.97 percentage points compared to the previous quarter [1] Group 1: Institutional Holdings - A total of 9 institutional investors have disclosed their holdings in Hotgen Biotech, with significant participants including Beijing Hotgen Biotech's repurchase account and various mutual funds [1] - The combined institutional holding percentage has decreased from the previous quarter, indicating a potential shift in investor sentiment [1] Group 2: Public Fund Holdings - Among public funds, 2 funds increased their holdings, accounting for a 0.76% increase, while 3 funds decreased their holdings, resulting in a 0.86% decrease [2] - A total of 284 public funds did not disclose their holdings this quarter, indicating a significant number of funds that may be reassessing their positions [2]

| | | 10月24日A股投资避雷针 | | --- | --- | --- | | 类别 | 公司 | 主要内容 | | | 沪硅产业 | 大基金拟减持不超2%公司股份 | | | 力芯微 | 控股股东亿晶投资拟减持不超3.00%股份 | | | 云路股份 | 郭克云拟减持不超3%股份 | | | 力量钻石 | 股东李爱真拟减持不超3%股份 | | | 国新能源 | 宏展房产拟减持不超2.07%股份 | | | 乐山电力 | 渤海信息产业基金合计减持0.8590%股份 | | 股东减持 | 宁波韵升 | 朱世东拟合计减持不超过11.18万股的股份 | | | 科威尔 | 合涂投资、京坤投资合计减持62.03万股股份 | | | 万华化学 | 合成国际减持合计1646.96万股股份 | | | 威尔药业 | 舜泰宗华已减持1%公司股份 | | | 复洁环保 | 隽洁投资减持合计281.33万股公司股份 | | | 华夏幸福 | 平安人寿及其一致行动人累计减持0.20%股份 | | | 星湖科技 | 股东铁小荣合计减持1912万股公司股份 | | 其他 | 甲投能源 | 独立董事韩放无法取得联系 | | | ...

证券日报网讯 10月23日晚间，热景生物发布公告称，公司于2025年10月23日召开第四届董事会第五次 会议审议通过《关于参股公司增资扩股实施股权激励暨关联交易的议案》。公司参股公司北京舜景生物 医药技术有限公司（简称"舜景医药"）拟通过新设立有限合伙企业（员工持股平台）对舜景医药进行增 资并实施股权激励，拟增资总金额为4，000万元，认购400万新增注册资本，差额部分计入资本公积。 公司拟放弃本次增资的优先认购权。公司控股股东、实际控制人、董事长、总经理林长青担任舜景医药 董事长。舜景医药拟设立的员工持股平台拟由林长青担任普通合伙人。公司作为舜景医药的股东，放弃 对舜景医药本次增资的优先认购权，构成关联交易。本次关联交易尚需提交股东会审议。 （文章来源：证券日报） ...

Major Events - Former Chairman of Beiyin Wealth Management, Fang Yi, has joined Huaxia Bank as Chief Risk Officer, pending regulatory approval [4] - Xilai Materials' subsidiary plans to invest 2 billion yuan in a semiconductor core component project, expected to generate over 1.5 billion yuan in annual output after reaching production [5][6] - Huatai Securities' subsidiary Huatai Futures has appointed Zhao Changtao as the new chairman [7] - Chuanfa Longmang's subsidiary plans to invest 366 million yuan in a 100,000 tons/year lithium dihydrogen phosphate project [8] - Huagong Technology is planning to issue H-shares and apply for listing on the Hong Kong Stock Exchange [9] - Jiangsu Leili's actual controller has changed from Su Jianguo to both Su Jianguo and Su Da due to internal share transfers [10] - Electric Power Investment Energy has been unable to contact independent director Han Fang, but this does not affect the board's operation [11] - Qiaqia Food's subsidiary is establishing an investment company focused on the leisure food industry with a total investment of 4 billion yuan [12][13] - Steel Research High-tech plans to set up a wholly-owned subsidiary in Saudi Arabia with an investment of up to 138 million yuan [14] - Yangjie Technology has terminated the acquisition of 100% equity in Better Electronics due to differences in business types and management [15] Performance Reports - Youfa Group reported a 2320.53% increase in net profit for Q3, despite a 3.97% decline in revenue [16] - Zhuoyi Information's net profit increased by 2074.65% in Q3, with revenue growth of 2.52% [17] - North Navigation's Q3 net profit surged by 1681.27%, with a 52.12% increase in revenue [18] - Tianneng Heavy Industry's net profit grew by 1359.03% in Q3, driven by increased sales of tower tubes [19] - Te Yi Pharmaceutical's net profit rose by 985.18% in Q3, with significant growth in traditional Chinese medicine sales [20] - Hualgreen Bio's Q3 net profit increased by 619.37%, with a 35.24% rise in revenue [21] - Zhenlei Technology's net profit grew by 598.09% in Q3, supported by strong revenue growth [22] - Shengyi Electronics expects a net profit increase of 476% to 519% for the first three quarters of 2025 [23] - Glodon reported a 244.89% increase in Q3 net profit, despite a slight decline in revenue [24] - Yingli Co., Ltd. saw a 229.14% increase in Q3 net profit, with a 14.73% rise in revenue [25] - Guangkang Biochemical's Q3 net profit increased by 236.87%, despite a decline in revenue [26] - High-speed Electric's Q3 net profit rose by 242.35%, with a 44.51% increase in revenue [27] - Wide Special Materials reported a 213.65% increase in net profit for Q3, driven by improved gross margins [28] - Baofeng Energy's Q3 net profit increased by 162.34%, attributed to increased production capacity [29] - Sanfu Co., Ltd. reported a 162.25% increase in Q3 net profit, driven by improved profitability of potassium and silane products [30] - Wuku New Energy's Q3 net profit increased by 106.31%, despite a loss in the first three quarters [32] - Pioneering Technology's Q3 net profit grew by 94.01%, supported by a recovery in the household energy storage market [33] - Sanlife Guojian's net profit increased by 71.15% in Q3, driven by project collaboration and CDMO business growth [34] - BGI Genomics reported a loss of 120 million yuan in the first three quarters, despite revenue growth [35] - Rejing Bio reported a net loss of 10.9 million yuan in the first three quarters, impacted by industry policies [36] - Jiangshan Oupai reported a net loss of 51.58 million yuan in Q3, attributed to market downturns and increased competition [38] - Taiping Bird reported a net loss of 49.45 million yuan in Q3, due to declining revenue and increased inventory losses [39] - Zhongke Tongda reported a loss of 6.87 million yuan in the first three quarters, affected by project delays and market competition [40] - Wolong New Energy reported a loss of 579.7 thousand yuan in Q3, transitioning from profit to loss [41] Major Contracts - Jinggong Steel Structure signed a significant overseas project contract worth approximately 1.23 billion yuan [42][43] - New Beiyang's subsidiary won a 105 million yuan postal equipment outsourcing project [44] - Maipu Medical plans to sign product sales agency agreements with related parties, with estimated procurement amounts of 21.5 million yuan and 3.5 million yuan [45] Shareholding Changes - Yunlu Co., Ltd. shareholder Guo Keyun plans to reduce his stake by up to 3% [46] Financing - Xinda Securities has received approval from the CSRC to issue up to 10 billion yuan in technology innovation corporate bonds [47]